Best in Biotech 11 Jun 2024
Finland: Pushing biotech forward in the land of a thousand lakes
Explore seven leading biotech companies driving Finland’s biotech sector forward in precision medicine, immunotherapy, and more.
Search Results for: Humanized antibody
In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
Best in Biotech 29 Feb 2024
6 biotech companies making a difference in pediatric care
Take a closer look at six pediatric companies taking innovative approaches to tackle illnesses affecting children.
News and Trends 30 May 2023
Potential targets against natural killer/T-cell lymphoma found
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly increased in patients with natural killer/T-cell lymphoma (NKTL). The increased TOX2 level leads to the growth and spread of NKTL, as well as the overproduction of […]
ADVERTISEMENT
News and Trends 8 Nov 2022
Lipum starts chronic inflammatory disease drug study
Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […]
News and Trends 26 Oct 2022
Scancell signs agreement with Genmab
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […]
News and Trends 6 Sep 2017
What to Do When the Microorganisms Get to You
For the first time ever an injectable clinical batch has been manufactured with the help of single-use technologies. A great way of fighting unwanted contamination in drug development! Have you ever opened a petri-dish and found an unknown growth on your medium? The same medium you had carefully prepared by meticulously spreading the sample over […]
News and Trends 18 May 2017
Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug
AptaTargets has closed a €2.7M funding round, allowing the biotech to move into the clinic with its first drug candidate for acute ischemic stroke. AptaTargets, located in Madrid, is developing new therapeutic applications based on aptamers. The company is currently focussing on a single lead candidate for the treatment of the acute phase of ischemic […]
In Depth 27 Apr 2017
Spain: An Emerging Star in the European Biotech Community
Take note, Spain is becoming a new hotspot for biotech in Europe. More than €400M of venture capital, counting recent fundraising and anticipated closings, is forecasted to be available this year to fund the creation and growth of start-ups in the life sciences sector. Behind the growing interest among investors are novel opportunities with breakthrough potential […]
More News! 8 Feb 2017
The First Stroke Drug in Decades? French Biotech gets closer to the Clinic
Acticor Biotech has raised €1.5M from CapDecisif Management, which will help its candidate for acute ischemic stroke enter Phase I trials. Acticor Biotech is a spin-off from the French National Institute of Health and Medical Research (Inserm) focusing on treating the acute phase of ischemic stroke, which occurs within the first few hours. The French VC firm CapDecisif Management has seen promise in […]
News and Trends 15 Jul 2016
UK Biotech buys Swiss Antibodies to accelerate CAR-T Development
Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field. Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and […]
News and Trends 16 Jul 2024
German biotech raises $150M on its way to tackle cancer therapy resistance
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.